Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0406810 (
NAME
)
13,345
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Downstream in-frame start codons produce amino-terminal-truncated human constitutive androstane receptor protein isoforms (DeltaNCARs). The DeltaNCARs are expressed in liver and in vitro cell systems following translation from in-frame methionine AUG start codons at positions 76, 80, 125, 128, 168 and 265 within the full-length
CAR
mRNA. The resulting
CAR
proteins lack the N-terminal DNA-binding domain (DBD) of the receptor, yielding DeltaNCAR variants with unique biological function. Although the DeltaNCARs maintain full retinoid X receptor alpha (RXRalpha) heterodimerization capacity, the DeltaNCARs are inactive on classical
CAR
-inducible direct repeat (DR)-4 elements, yet efficiently transactivate a
DR-1
element derived from the endogenous PPAR-inducible acyl-CoA oxidase gene promoter. RXRalpha heterodimerization with CAR1, CAR76 and CAR80 isoforms is necessary for the
DR-1
PPRE activation, a function that exhibits absolute dependence on both the respective RXRalpha DBD and
CAR
activation (AF)-2 domains, but not the AF-1 or AF-2 domain of RXRalpha, nor
CAR
's DBD. A new model of
CAR
DBD-independent transactivation is proposed, such that in the context of a
DR-1
peroxisome proliferator-activated response element, only the RXRalpha portion of the
CAR
-RXRalpha heterodimer binds directly to DNA, with the AF-2 domain of tethered
CAR
mediating transcriptional activation of the receptor complex.
...
PMID:Transactivation of a DR-1 PPRE by a human constitutive androstane receptor variant expressed from internal protein translation start sites. 1735 85